Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NM-520
- Development stage
- Preclinical
- Lead developer
- Speratum Biopharma
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
NM-520 is a discovery-stage therapeutic candidate being developed by Speratum Biopharma. As of early 2024, specific details regarding its molecular target, mechanism of action, and primary clinical indications remain undisclosed by the developer. The asset is part of Speratum's pipeline of RNA-based therapeutics, which typically utilizes a proprietary nanoparticle delivery platform to administer oligonucleotide-based drugs, such as microRNA (miRNA) mimics or small interfering RNAs (siRNAs). Given the company's focus on oncology with its lead candidate NM-198, it is anticipated that NM-520 is being explored for the treatment of cancer or other complex diseases with high unmet medical needs.
Beyond the preview
Go deeper on NM-520.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NM-520.